MXN tablets

Dexa Medica

Composition

Moxifloxacin400 mg

Each Pack Contains

1 strip of 10 caplets

Dosage Form

caplet

Dosage formCaplet

Flavor

None

W.H.O. Classification

J01M

Available In

Indonesia

Warning

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Indication

Moxifloxacin is indicated for the treatment in adults (> 18 years of age) for the following bacterial infections:
Upper respiratory tract infections
– Acute exacerbations of chronic bronchitis
– Community-acquired pneumonia
– Acute sinusitis
Skin and soft tissue infections
Moxifloxacin is indicated for the treatment of the infections caused by bacteria susceptible to moxifloxacin.

Dosage

UP TO 18 YEARS
Efficacy and safety of moxifloxacin in children and adolescents have not been established.

18 YEARS OLD AND ABOVE
The recommended dose for moxifloxacin is one 400 mg tablet once daily.

For treatment of skin and soft tissue infections requiring initial intravenous therapy followed by administration of 400 mg moxifloxacin tablet.

The recommended dose (400 mg once daily) and duration of therapy for the indication being treated should not be exceeded

65 YEARS OLD AND ABOVE
No adjustment of dosage is required in elderly patients.

ADMINISTRATION
The film-coated tablets should be swallowed whole with sufficient liquid and may be taken independent of meals.

DURATION OF TREATMENT
Moxifloxacin tablet should be used for the following treatment durations:
— Acute exacerbation of chronic bronchitis:
5-10 days
— Community-acquired pneumonia:
10 days
— Acute sinusitis:
7 days
— Complicated skin and soft tissue:
7-21 days

PATIENTS WITH RENAL IMPAIRMENT
No dosage adjustment is required in patients with renal impairment (creatinine clearance ≤30 ml/minute/1.73m²).